Investigation of Reports to VAERS of Death after Vaccination

Similar documents
Responding to Vaccine Safety Events

Assessing the Safety of Vaccines at the FDA: Pre- and Post-Licensure Evaluation

Immunization Safety Office: Overview and Considerations on Safety of Alternative Immunization Schedules

Protecting Infants and Children from Pertussis and Influenza

TITLE 64 INTERPRETIVE RULE DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR PUBLIC HEALTH

Update on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017

Adolescent vaccination strategies

OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE

Deployment of Combination Vaccines and STI vaccines

Perspectives on Improving International Vaccine Safety

Assessing Vaccine Safety Post Licensure. Neal A. Halsey Johns Hopkins University

Vaccine Safety Datalink (VSD)

Recommended Childhood Immunization Schedu...ates, January - December 2000, NP Central

The Relationship Between Pertussis Vaccine and Central Nervous System Sequelae: Continuing Assessment

An Update: Recommended Immunization Schedules. Birth to Age 18

3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups

Decision-making by the Advisory Committee on Immunization Practices

The Hepatitis B Vaccine: What Went Wrong?

WHY WE RE HERE. Melinda Wharton, MD, MPH Director, Immunization Services Division. National Center for Immunization & Respiratory Diseases

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

Routine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002

Vaccine Safety: Its everyone s business! PHO Rounds: Nov 19, 2013

NOTE: The above recommendations must be read along with the footnotes of this schedule.

MMWR. 2009;58(RR02):1-25.

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.

2013 About Pertussis (Whooping Cough)

Mandates and More. Julie Morita, M.D. Deputy Commissioner Chicago Department of Public Health. Chicago Department of Public Health

Influenza Vaccine Safety Monitoring Update

The Childhood Immunization Schedule and the National Immunization Survey

NOTE: The above recommendations must be read along with the footnotes of this schedule.

RSV Surveillance in the U.S.

Note from the National Guideline Clearinghouse (NGC): The guideline recommendations are presented in the form of tables with footnotes (see below).

Immunizing the Immunocompromised. Leilani T. Sanchez, MD, DPPS, DPIDSP Crowne Plaza Galleria Manila, 21 February 2013

Objectives. Immunity. Childhood Immunization Risk of Non-Vaccinated Children 12/22/2015

HOW DO VACCINES WORK?

THE FOOD AND DRUG ADMINIStration

2017 Vaccine Preventable Disease Summary

HPV Free ID. Toolkit for Increasing HPV Vaccination Rates in Idaho. Toolkit for Increasing HPV Vaccination

MDPH Influenza Update

Vaccine Innovation: Challenges and Opportunities to Protect Health. Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines

De-Sexualizing the HPV Vaccine How to Counsel Your Families

VACCINATION FOR WOMEN (ADOLESCENCE TO SENESCENCE)

What DO the childhood immunization footnotes reveal? Questions and answers

IOM Committee on Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule

Current Incident Status of Vaccine-Preventable Bacterial and Viral Infectious Diseases in Japan

Incidence of GBS and CIDP following influenza vaccination

UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES

301 W. Alder, Missoula, MT or

Georgia State University. Georgia State University. Jorge E. Arana. Spring

Approaches to Assessing Intussusception Risk in Developing Countries

For Residence Hall Students Only

GENERAL SAFETY ISSUES September 18, 2009

Pertussis Epidemiology and Vaccination in the United States and the Latin American Pertussis Project

Measles: United States, January 1 through June 10, 2011

Current (+ Future) Vaccine Safety Data Sources. Robert T. Chen MD, MA Vaccine Safety and Development Activity National Immunization Program

Healthcare Personnel Immunization Recommendations

Faculty / Presenter Disclosure. Disclosure of Commercial Support. Mitigating Potential Bias

National Vaccine Plan: From Strategy to Implementation

Safety monitoring of vaccines. Jeremy Labadie MD vaccine safety specialist

Immunization Accomplishments and Challenges, 2017

Lessons Three and Four Safety, Health, and Care parts 1 and 2 (2 class periods)

S. Michael Marcy Memorial Lecture

Objectives. Immunity. Diphtheria. Immunization Update July 22, Individual Immunity

Achievements in Public Health, Impact of Vaccines Universal... Children -- United States,

ACIP Meeting Update, New Recommendations and Pending Influenza Season

Seasonal Influenza Report

3. Rapidly recognize influenza seasons in which the impact of influenza appears to be unusually severe among children.

NYS Trends in Vaccine Preventable Disease Control

Immunizations are among the most cost effective and widely used public health interventions.

2016 Vaccine Preventable Disease Summary

ASANTE WIDE Document Number 400-EH-0312

Definition of Standing Order

Lessons Learned from Adverse Events and Assessment of Causal Relationships. Neal A. Halsey Johns Hopkins University

Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development Associate Director, Emory Vaccine Center

Tennessee Immunization Program Updates

Seasonal Influenza and Tdap Vaccination Policies in Michigan Hospitals: MDCH Hospital Survey, Fall 2011

Immunization Report Public Health September 2013

APEC Guidelines Immunizations

Immunization Update Richard M. Lampe M.D.

Missouri Newborn Blood Spot Screening. Missouri Department of Health and Senior Services Bureau of Genetics and Healthy Childhood September 21, 2017

What s New In Pediatric Vaccines? and Addressing Vaccine Hesitancy

Chickenpox vaccine for all?

Vaccine Information Statement: PEDIATRIC VACCINES (Multiple)

7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids

SUPPLEMENT ARTICLE METHODS

The Use of Combination Vaccines in the United States

A. Children born in 1942 B. Children born in 1982 C. Children born in 2000 D. Children born in 2010

Travel. Program Management. Schedule

Downloaded from:

These slides are the property of the presenter. Do not duplicate without express written consent.

US Rotavirus Vaccination Program

Vaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications

F.A.S.N. annual conference 2009 Alix Casler, M.D., F.A.A.P. Orlando, FL

Disclosures. Vaccines Save Lives, So Why the Pushback and What to do About It? Learning Objectives. ACIP History and Charge

Public Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04.

Management and Reporting of Vaccine Preventable Diseases in Schools. Shirley A. Morales,MPH,CIC

Alaska Statewide Maternal Child Health & Immunization Conference. Doreen Stangel Lorraine Alfsen September 23, 2008

2017 SCAAP Summer Conference. Lilian Peake, MD, MPH

Prevention of Infections in Mothers & Infants

Pertussis: An Emerging Infection. Holly K. Ehrke. Ferris State University

Transcription:

Investigation of Reports to VAERS of Death after Vaccination Robert Ball, MD, MPH, ScM Chief, Vaccine Safety Branch Office of Biostatistics and Epidemiology for IOM Immunization Safety Review Committee October 28, 2002

What is the Vaccine Adverse Event Reporting System (VAERS)? National system for surveillance of adverse events after vaccination initiated by National Childhood Vaccine Injury Act 1986 and established 1990 Jointly managed by FDA and CDC Reports received from health professionals, vaccine manufacturers, and the public All death and serious (hospitalization, prolongation of hospitalization, life-threatening illness, or permanent disability ) reports receive follow-up

Uses of VAERS Detecting unrecognized adverse events Monitoring known reactions Identifying possible risk factors Vaccine lot surveillance

Limitations of VAERS Reported diagnoses are not verified Lack of consistent diagnostic criteria Wide range in data quality Underreporting Inadequate denominator data No unvaccinated control group Usually not possible to assess whether a vaccine caused the reported adverse event

Analysis of VAERS Data Describe characteristics and look for patterns to detect signals of adverse events plausibly linked to a vaccine Signals detected through analysis of VAERS data almost always require confirmation through a controlled study

Background When apparently healthy people die shortly after immunization, it is reasonable to ask if the vaccine caused or contributed to the death Controlled studies of vaccines do not show increased risk of death among vaccinees The widespread administration of vaccines may result in some temporal, but not causal, associations with deaths It is possible that vaccination rarely causes death at rates too low to allow detection in controlled studies Reports of death after vaccination to VAERS provide an opportunity to possibly detect such cases

Background (cont.) The FDA and the Institute of Medicine (IOM) reviewed 206 deaths reported to VAERS during 1990-1991. One death was believed to have resulted from a vaccine The IOM concluded that the vast majority of deaths reported to VAERS are temporally but not causally related to vaccination. Institute of Medicine. Editors: Stratton KR, Howe CJ, Johnston RB, Jr. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. National Academy Press: Washington, DC. 1994; P.274-304.

The Epidemiology of Fatalities Reported to VAERS 1990-1997 1, 266 fatalities reported to VAERS Median age 0.4 years (range 1 day to 104 years) Higher percentage of deaths reported to VAERS (16.8%) in low-birth weight infants than US general population Nearly half of reported deaths attributed to SIDS Number of reported deaths peaked in 1992-1993 Pattern follows the decline in deaths in the US attributed to SIDS since Back to Sleep program Conclusion: Data support prior controlled studies showing that association between infant vaccination and SIDS is not causal Silvers LE, Ellenberg SS, Wise RP, Varriccho FE, Mootrey GT, Salive ME. The epidemiology of fatalities reported to the Vaccine Adverse Event Reporting System 1990-1997. Pharmacoepidemiology and Drug Safety. 2001; 10:279-285.

Reported Deaths after Vaccination by Age and Gender (VAERS, US 1990-1997) Age in Years n Percentage Percentage female Overall 1199 100.0 42 < 1 808 67.4 39 1 4 117 9.8 43 5 9 18 1.5 50 10 17 17 1.4 29 18 45 43 3.6 56 46 64 55 4.6 44 > 65 141 11.7 55 Excludes 67/1266 cases with unreported age. The stratification by gender excludes 28/1199 cases due to unreported gender

Causes of Death (VAERS, US 1990-1997) Cause of Death n Percentage Percentage female Overall 1244 100.0 42 SIDS 592 47.6 36 Congenital 38 3.1 46 Infectious 164 13.2 42 Neoplastic 15 1.2 67 Other 261 21.0 48 Unknown 147 14.0 48 Gender was unknown for 53 cases. Cases with unknown gender were excluded for this calculation.

Pediatric Deaths Reported after Vaccination: The Utility of Information Obtained from Parents Structured interviews of parents and healthcare providers (HCP) of 100 consecutive pediatric deaths reported to VAERS to determine value of parental information compared with HCP information In general the information was equivalent in quality Parents were more likely to know child s position when found in distress Conclusion: None of the additional information obtained from parents provided a signal or confirmation of a causal link between vaccine and death Silvers LE, Varriccho FE, Ellenberg SS, Krueger CL, Wise RP, Salive ME. Pediatric deaths reported after vaccination: The utility of information obtained from parents. American Journal of Preventive Medicine 2002; 22:170-176.

Neonatal Deaths after Hepatitis B Vaccine: VAERS, 1991-1998 18 deaths in 1,771 neonatal reports 8 boys, 9 girls, 1 unclassified 17 Autopsy Reports 12 SIDS, 3 infection, 1 intracerebral hemorrhage, 1 accidental suffocation, 1 congenital heart disease Conclusion: No evidence to suggest Hepatitis B vaccination implicated in neonatal deaths Niu MT, Salive ME, Ellenberg, SS. Neonatal deaths after hepatitis B vaccine: the Vaccine Adverse Event Reporting System, 1991-1998. Archives of Pediatrics and Adolescent Medicine. 1999; 153:1279-82.

Published Surveillance Summaries Including Review of Reports of Death Following Vaccination Ball R, Braun MM, Mootrey GT (2001). Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System. Clin.Infect.Dis., 32(9), 1273-1280. Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS (2000). Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics, 106(4), E51 Lathrop SL, Ball R, Haber P, Mootrey GT, Braun MM, Shadomy SV, Ellenberg SS, Chen RT, Hayes EB. (2002). Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. Vaccine, 20(11-12), 1603-1608. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, Krause PR. (2000). Postlicensure safety surveillance for varicella vaccine. JAMA, 284(10), 1271-1279. Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M (2001). Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatrics, 107(6), E97

Follow-up Procedures for Reports to VAERS of Death after Vaccination Contract nurse-initiated follow-up of all serious cases including death Documents requested (where appropriate) Medical records Discharge summary Death Certificates Autopsies/Medical Examiner reports Misc (ER records, physician notes/summaries, consultant reports) Standardized data collection instruments completed Adult death supplemental follow-up questionnaire Pediatric death supplemental follow-up questionnaire

Follow-up Results 10/1/00-9/30/02 562 initial reports of death 163 Autopsy Reports Received (29.0%) Avg Time 67.2 Days Of the 562 17 or younger - 413 (73.5%) 18 or older - 113 (20.l%) No Response 36 (6.4%)

Review of Reports to VAERS of Death after Vaccination FDA pathologist reviews all reports and associated documentation as information arrives FDA medical officers review deaths reported for vaccines they monitor on a weekly basis Review of reported deaths by lot at weekly meeting If 3 or more deaths are reported in a given lot, the reports are examined for unexpected patterns in causes of death and reporting rate by lot, if warranted

Death Reports of Interest Yellow fever vaccine-associated viscerotropic disease Vaccine strain virus detected in tissue Martin M, Tsai TF, Cropp B, et al. Fever and Multisystem Organ Failure associated with 17D-204 yellow fever: A report of four cases. Lancet 2001; 358:98-104. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA and Rowlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001; 358: 121-2. Intussusception after Rotavirus vaccine 1 death from intussusception but not possible to conclusively determine if caused by vaccine VAERS has limited ability to detect rare events

Summary Limitations of VAERS prevent definitive assessment of vaccine causality However, intensive review of death reports and vaccine surveillance summaries have found no clear evidence of an association between vaccination and death except in rare instances (e.g. yellow fever vaccine and viscerotropic disease) Routine follow-up and review of reports and lotspecific screening continues to be conducted by FDA medical officers

Acknowledgements Analytical Sciences, Inc (VAERS contractor) Steve Gordon FDA Sean Shadomy, Bob Wise, M. Miles Braun, Susan Ellenberg